Literature DB >> 23602628

A higher correlation of the antibody activities against the calcium-dependent epitopes of desmoglein 3 quantified by ethylenediaminetetraacetic acid-treated enzyme-linked immunosorbent assay with clinical disease activities of pemphigus vulgaris.

Koji Kamiya1, Yumi Aoyama, Yoshinori Shirafuji, Toshihisa Hamada, Shin Morizane, Kazuyasu Fujii, Keiji Iwatsuki.   

Abstract

BACKGROUND: Nonpathogenic anti-desmoglein (Dsg) 3 antibodies can be found in pemphigus vulgaris (PV) patients' sera. Previously, ethylenediaminetetraacetic acid (EDTA)-treated enzyme-linked immunosorbent assay (ELISA) was found to detect only nonpathogenic anti-Dsg3 antibodies against the non-calcium (Ca(2+))-dependent epitopes.
OBJECTIVE: We examined whether the calculated anti-Dsg3 antibody titer for Ca(2+)-dependent epitopes, using the conventional and EDTA-treated ELISAs, correlated better with the disease activity of PV.
METHODS: We analyzed 123 serum samples from 19 PV patients. Of these samples, there were 52 samples from 15 PV patients obtained in asymptomatic phases. The difference between conventional Dsg3 ELISA index and EDTA-treated Dsg3 ELISA index was calculated as the anti-Dsg3 antibody activity for Ca(2+)-dependent conformational epitopes (conformational Dsg3 ELISA index). We analyzed the correlation between Dsg3 ELISA index values and the pemphigus disease area index (PDAI). Moreover, we examined whether the conformational Dsg3 ELISA index fluctuated in parallel with the disease activity during clinical courses of 6 PV patients. We evaluated the pathogenicity of anti-Dsg3 antibodies detected in remission phases using a dissociation assay.
RESULTS: The conventional Dsg3 ELISA index showed a high positive rate in the asymptomatic phase of PV. By contrast, the conformational Dsg3 ELISA index showed a much closer correlation to the disease activity when monitored in individual cases. Nonpathogenic anti-Dsg3 antibodies were detected in these cases.
CONCLUSION: The conformational Dsg3 ELISA index reflected the pathogenicity of anti-Dsg3 antibodies more accurately than the conventional Dsg3 ELISA index. Using both conventional and EDTA-treated ELISAs would be useful in monitoring the disease activity of PV.
Copyright © 2013 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23602628     DOI: 10.1016/j.jdermsci.2013.02.011

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  10 in total

Review 1.  Pemphigus: a Comprehensive Review on Pathogenesis, Clinical Presentation and Novel Therapeutic Approaches.

Authors:  Robert Pollmann; Thomas Schmidt; Rüdiger Eming; Michael Hertl
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

Review 2.  Mechanisms of Disease: Pemphigus and Bullous Pemphigoid.

Authors:  Christoph M Hammers; John R Stanley
Journal:  Annu Rev Pathol       Date:  2016-02-22       Impact factor: 23.472

Review 3.  Pemphigus.

Authors:  Michael Kasperkiewicz; Christoph T Ellebrecht; Hayato Takahashi; Jun Yamagami; Detlef Zillikens; Aimee S Payne; Masayuki Amagai
Journal:  Nat Rev Dis Primers       Date:  2017-05-11       Impact factor: 52.329

Review 4.  Pemphigus and Pemphigoid: From Disease Mechanisms to Druggable Pathways.

Authors:  Christoph T Ellebrecht; Damian Maseda; Aimee S Payne
Journal:  J Invest Dermatol       Date:  2021-10-29       Impact factor: 7.590

Review 5.  Immune response in pemphigus and beyond: progresses and emerging concepts.

Authors:  Giovanni Di Zenzo; Kyle T Amber; Beyza S Sayar; Eliane J Müller; Luca Borradori
Journal:  Semin Immunopathol       Date:  2015-11-23       Impact factor: 9.623

Review 6.  Autoimmune Pemphigus: Latest Advances and Emerging Therapies.

Authors:  Yen Loo Lim; Gerome Bohelay; Sho Hanakawa; Philippe Musette; Baptiste Janela
Journal:  Front Mol Biosci       Date:  2022-02-04

7.  Autoantibodies against Desmoglein 1 and 3 in South Tunisian pemphigus.

Authors:  Ameni Jerbi; Hend Hachicha; Sawsan Feki; Olfa Abida; Emna Bahloul; Khadija Sellami; Amina Bouzid; Hamida Turki; Abderrahmen Masmoudi; Hatem Masmoudi
Journal:  Tunis Med       Date:  2021 Octobre

Review 8.  Mechanisms Causing Acantholysis in Pemphigus-Lessons from Human Skin.

Authors:  Desalegn Tadesse Egu; Thomas Schmitt; Jens Waschke
Journal:  Front Immunol       Date:  2022-05-20       Impact factor: 8.786

Review 9.  Autoantibody Signaling in Pemphigus Vulgaris: Development of an Integrated Model.

Authors:  Thomas Sajda; Animesh A Sinha
Journal:  Front Immunol       Date:  2018-04-19       Impact factor: 7.561

10.  Short-term clinical and serological follow-up with conventional and conformational anti-desmoglein antibodies in treatment-naïve and previously treated patients with pemphigus vulgaris after receiving rituximab.

Authors:  Hoorieh Alaeen; Roja Toosi; Hamidreza Mahmoudi; Kamran Balighi; Soheil Tavakolpour; Amir Teimoupour; Maryam Daneshpazhooh
Journal:  Int J Womens Dermatol       Date:  2019-06-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.